Thomas A. Dineen

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Meredith S. Eno, Jason D. Brubaker, John E. Campbell et al. · Journal of Medicinal Chemistry · 2022 · 160 citations · Full text

Medicine, Oncology, Pharmacology +14

Efficient Transamidation of Primary Carboxamides by in Situ Activation with <i>N</i>,<i>N</i>-Dialkylformamide Dimethyl Acetals

Thomas A. Dineen, Matthew Zajac, Andrew G. Myers · Journal of the American Chemical Society · 2006 · 148 citations

Natural Sciences, Chemistry, Medicinal Chemistry +11

Sulfonamides as Selective Na_V1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity

Russell F. Graceffa, Alessandro A. Boezio, Jessica Able et al. · Journal of Medicinal Chemistry · 2017 · 69 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Structure- and Property-Based Design of Aminooxazoline Xanthenes as Selective, Orally Efficacious, and CNS Penetrable BACE Inhibitors for the Treatment of Alzheimer’s Disease

Hongbing Huang, Daniel S. La, Alan C. Cheng et al. · Journal of Medicinal Chemistry · 2012 · 68 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Design and Preparation of a Potent Series of Hydroxyethylamine Containing β-Secretase Inhibitors That Demonstrate Robust Reduction of Central β-Amyloid

Matthew M. Weiss, Toni Williamson, Safura Babu‐Khan et al. · Journal of Medicinal Chemistry · 2012 · 64 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17